BioCentury | Nov 14, 2019
Targets & Mechanisms

New roles for HDACs in the cytoplasm and muscle disorders

While HDACs are known for their epigenetic function, NIBR researchers have discovered cytoplasmic HDAC4 substrates involved in muscle physiology. The findings suggest blocking HDAC4 deacetylation activity could treat muscle atrophy and other musculoskeletal disorders. HDACs...
BioCentury | Apr 7, 2017
Strategy

Pushing for progress in Prader-Willi

In the wake of the 2015 clinical failure of Zafgen Inc. ’s subcutaneous beloranib for obesity in Prader-Willi syndrome patients, the Foundation for Prader-Willi Research (FPWR) last year launched a five-year, $26 million strategic research...
BioCentury | Oct 8, 2015
Targets & Mechanisms

Nuclear blockade unlocked

...RNA repeats bind and block the function of neuroprotective proteins. Because RANGAP1 is required for nuclear protein...
BioCentury | Oct 1, 2015
Distillery Therapeutics

Therapeutics: Chromosome 9 open reading frame 72 (C9orf72)

...and Drosophila harboring the C9orf72 expansions identified loss-of-function and gain-of-function mutations of genes involved in nuclear protein...
...suppressed or enhanced neurotoxicity, respectively. In human neurons generated from induced pluripotent stem (iPS) cells, nuclear protein...
BioCentury | Aug 1, 2013
Targets & Mechanisms

Activating memory

Despite more than a decade of research suggesting histone acetyltransferases play a role in learning and memory, the targets have proven difficult to selectively activate in the brain. Now, a French and Indian team has...
BioCentury | Aug 9, 2012
Targets & Mechanisms

Isis takes on myotonic dystrophy

Researchers at the University of Rochester and Isis Pharmaceuticals Inc. have come up with an efficient way to treat symptoms of myotonic dystrophy type 1 in mice using systemically delivered antisense oligonucleotides. 1 The finding...
BioCentury | Jul 6, 2012
Financial News

Inbiomotion raises EUR 2 million in series A

...primary tumor biopsies. The company has validated its lead biomarker, which codes for an undisclosed nuclear protein. BC...
BioCentury | Jan 7, 2010
Tools & Techniques

Going live with aptamers

...1 Using the approach, the group identified an RNA aptamer that binds to a tumor-associated nuclear protein...
BioCentury | Apr 30, 2009
Targets & Mechanisms

Extinguishing neuroinflammation

U.S. and Australian teams have elucidated the pathway that leads to microglia activation, an early step in inflammatory neurodegenerative disorders. The studies suggest that dampening microglial activity early in disease could spare nearby neurons from...
BioCentury | Jan 29, 2009
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection; lupus Hematopoietic interferon-inducible nuclear proteins with a 200-amino-acid repeat (HIN-200) gene family; tumor protein p53 binding protein 1...
Items per page:
1 - 10 of 24